City of Toronto  

Living in TorontoDoing businessVisiting TorontoAccessing City Hall
 
All news releases
Last 30 days
By month
Search
   
Newsroom
   
Archived news release by year
  2013
  2012 - 2011 - 2010
  2009 - 2008 - 2007
  2006 - 2005 - 2004
  2003 - 2002 - 2001
  2000 - 1999 - 1998
   
RSS identifier linked to feed RSS
   
   
 
February 20, 2002
Media Advisory: Pharmacogenetics: custom drugs -- fact or fiction?
  
Date: Thursday, February 21

Time: 8 to 10 a.m.

Registration: 7:30 a.m.

Place: Metro Hall, 55 John St.
3rd floor, room 308/309

Michael Dennis, Ph.D., CEO of SignalGene Inc., a Montreal-based,
publicly-traded genomics drug discovery company, and Bruno Maruzzo, Director of
Investor Relations at Visible Genetics Inc., will discuss pharmacogenetics at
the Toronto Biotechnology Initiative's February breakfast meeting.

Pharmacogenetics is the use of genetic information in diagnosis and treatment.
People are genetically different and they can react differently to the same
drug. Polar and adverse response to drugs is the fourth largest killer in the
United States. Pharmacogenetics is part of the bio-tech community's strategy to
develop new drugs that eliminate or minimize polar and adverse responses.


Media Contact
Access Toronto
416-338-0338

 

 

Toronto maps | Get involved | Toronto links
© City of Toronto 1998-2019